

## Cloning and sequencing of *Lol pI*, the major allergenic protein of rye-grass pollen

Irwin J. Griffith<sup>1</sup>, Penelope M. Smith<sup>2</sup>, Joanne Pollock<sup>1</sup>, Piyada Theerakulpisut<sup>2</sup>, Asil Avjioglu<sup>2</sup>, Sean Davies<sup>2</sup>, Terryn Hough<sup>2</sup>, Mohan B. Singh<sup>2</sup>, Richard J. Simpson<sup>3</sup>, Larry D. Ward<sup>3</sup> and R. Bruce Knox<sup>2</sup>

<sup>1</sup>ImmuLogic Pharmaceutical Corporation, One Kendall Square, Building 600, Cambridge, MA 02139, USA, <sup>2</sup>School of Botany, University of Melbourne, Parkville, Victoria 3052, Australia and <sup>3</sup>Joint Protein Structure Laboratory, Ludwig Institute for Cancer Research (Melbourne Branch) and The Walter and Eliza Hall Institute for Medical Research, Parkville, Victoria 3052, Australia

Received 5 December 1990

We have isolated a full length cDNA clone encoding the major glycoprotein allergen *Lol pI*. The clone was selected using a combination of immunological screening of a cDNA expression library and PCR amplification of *Lol pI*-specific transcripts. *Lol pI* expressed in bacteria as a fusion protein shows recognition by specific IgE antibodies present in sera of grass pollen-allergic subjects. Northern analysis has shown that the *Lol pI* transcripts are expressed only in pollen of rye-grass. Molecular cloning of *Lol pI* provides a molecular genetic approach to study the structure-function relationship of allergens.

*Lolium perenne*; Allergen; cDNA cloning; Nucleotide sequence; Amino acid sequence

### 1. INTRODUCTION

Hayfever and seasonal allergic asthma due to grass pollen allergens are environmental diseases that afflict up to 25% of the population in cool temperate climates [1-3]. Although a degree of cross-reactivity has been described among antigens from different grass species [4-6], it is well established that rye-grass antigens are the most reactive allergens [7,8]. The most prominent allergen in rye-grass pollen is group I or *Lol pI* (IUIS nomenclature [9]). This has been shown to be the major IgE-binding protein [7,8]. Elevated levels of *Lol pI*-specific IgE have been detected in sera of up to 95% of grass pollen-allergic individuals, and thus of major clinical significance [7,8]. Other clinically significant allergens of rye-grass include *Lol pII*, *III*, *IV* [9] and the newly identified *Lol pIb* [10].

*Lol pI* is an abundant acidic glycoprotein of *M*<sub>r</sub> 35 kDa [8] and *pI* 5.5 [10], located in the cytosol of the pollen [10,11]. The amino acid sequence of this allergen has not been reported, although short sequences from an N-terminal and an internal peptide fragment have been determined [12,13]. In this paper, we report the cloning, expression and sequencing of a full-length cDNA clone encoding *Lol pI*.

### 2. MATERIALS AND METHODS

#### 2.1. Plant materials and antibody probes

Pollen of *Lolium perenne* was collected from plants flowering in Melbourne, and stored in liquid nitrogen until used. MAbs 40.1, 21.3 and 3.2 are specific for *Lol pI*, and their preparation and characterization have been described elsewhere [4,10,14-16]. IgE antibodies were from sera of grass pollen-allergic individuals, as determined by skin prick test and/or RAST (Radioallergosorbent test).

#### 2.2. Isolation of pollen proteins and immunoblotting

Soluble proteins were extracted from rye-grass pollen by vigorous shaking in PBS (150 mM, pH 7.2) containing 1 mM PMSF, on ice for 3 h. Conditions for electrophoresis and immunoblotting with MAbs were essentially as described [16]. For IgE antibody binding, blots were incubated in allergic sera collected from at least 4 patients with high RAST scores for grass pollen, pooled and used diluted 1:5 in TBS/0.5% BSA. The bound IgE was detected using <sup>125</sup>I-labelled anti-human IgE (Kallestad, USA) essentially as described by Ford and Baldo [8].

#### 2.3. Purification of *Lol pI* for N-terminal sequencing

*Lol pI* was isolated using preparative isoelectric focussing (Rotofor, BioRad, Richmond, CA) followed by SDS-PAGE (A. Avjioglu and M.B. Singh, unpublished data). The allergen was recovered from SDS-PAGE gels by electrotransfer (90 V/2 h; 4°C) onto polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA) [17]. Proteins were visualized by staining with Coomassie brilliant blue R-250, washed extensively with deionized water [17] and subjected to sequence analysis [17,18]. Amino acid residues are given using the one letter notation.

#### 2.4. cDNA library and immunological screening

Poly (A<sup>+</sup>) mRNA was isolated essentially as described [19]. cDNA was synthesized [20] and cloned into the *EcoRI* site of the vector lambda-gt 11. Immunological screening was done by plating the

Correspondence address: R.B. Knox, School of Botany, University of Melbourne, Parkville, Victoria 3052, Australia.

cDNA library, and screening duplicate filters with MAb 40.1, using peroxidase-labelled anti-mouse Ig as secondary antibody. The plaques that were antibody-positive on both of the duplicate filters were picked off, purified, then replated and tested for binding to other MAbs as well as IgE antibodies.

### 2.5. Nucleotide sequencing

The cDNA clone 13R was isolated from the phage, and subcloned into pGEM-3Z vectors (Promega). DNA sequence was determined by double-stranded sequencing carried out by the dideoxy chain termination method [21], using T7 DNA polymerase (Pharmacia). PCR amplified DNA was cloned into M13 vector for dideoxy sequencing using sequenase (US Biochemicals).

### 2.6. Oligonucleotides

Oligonucleotides used in this study are shown in Table 1. Anchor Primer (AP), Anchor Linker (AL) and Anchor Template (AT) have been described previously [22]. LpA-3 and LpA-5 were derived from the sequence of the *Lol pI* cDNA clone 13R. Sequencing primers were derived from the internal sequence of PCR-generated clones. All oligomers were purchased from Research Genetics (Huntsville, AL, USA).

### 2.7. Polymerase chain reaction (PCR) cloning

Full length clones encoding *Lol pI* were obtained using a modification [22] of the Anchored PCR [23,24]. Double stranded cDNA was synthesized from 1 µg of total RNA with the cDNA Synthesis System (Life Technologies, Inc., Gaithersburg, MD, USA) using oligo dT as a primer, blunt ended with T4 polymerase and blunt end ligated to self-annulated AT and AL primers. Linkered cDNA (3 µl from a 20 µl reaction) was mixed with 100 pmol each of AP and LpA-5 primers, 10 µl of 10X reaction buffer (GeneAmp kit, US Biochemicals, Cleveland, OH, USA) and 0.5 µl of *T. aquaticus* polymerase. The mixture was brought to 100 µl with deionized water and amplified for 25 cycles as described [22]. Briefly, the first 5 cycles consisted of denaturation at 94°C for 1 min, annealing at 45°C for 1.5 min, and polymerization at 70°C for 1.5 min. The last 20 cycles were as stated, except that annealing was at 55°C. 0.01 volume of the primary PCR was then reamplified with oligomers AP and LpA-3 as above. LpA-3 is nested (internal) relative to oligomer LpA-5 used in the primary PCR. DNA from the secondary PCR was recovered by sequential chloroform, phenol and chloroform extractions, precipitated with 0.5 vol. 7.5 M AmOAc and 1.5 vol. isopropanol. DNA from the pellet was digested with *Xba* I and *Pst* I, run on a preparative low melt gel, and ligated into *Xba* I/*Pst* I-digested M13.

## 3. RESULTS

### 3.1. Identification of *Lol pI* by immunoblotting

The recombinant clone (13R) was isolated using *Lol pI*-specific MAbs, which provides evidence of its rela-




Fig. 1. Immunoblot analysis of IgE and MAb binding to *Lol pI* proteins from rye-grass pollen. *M<sub>r</sub>* (kDa) is denoted on the left. 120 µg of pollen proteins were loaded per lane. *Lol pI* is denoted with an arrow. Lane 1: SDS-separation of total rye-grass pollen proteins (staining is with Coomassie brilliant blue R-250); lanes 2-5: binding of MAbs or IgE on Western blots of total rye-grass pollen proteins.

tionship to the native allergen. On Western blots of pollen proteins, MAbs 3.2, 21.3 and 40.1 show strong affinity for a 35-kDa protein (Fig. 1). This protein showed high specificity for IgE antibodies from pooled sera of grass pollen-allergic individuals (Fig. 1). All the MAbs and IgE used in this study bound strongly to the *Lol pI* reference standard provided by NIAID (National Institutes of Health, Bethesda, MD; data not shown).

### 3.2. N-terminal sequence of *Lol pI*

We purified *Lol pI* by two-dimensional gel electrophoresis involving preparative isoelectric focussing in the first dimension, followed by SDS-PAGE of the individual fractions. This procedure successfully


Table 1  
Oligonucleotide sequences

Oligomer	Nucleotide sequence	Strand	Nucleotides
AL	5' p-AATGATCGATGCT	-----	-----
AP	5' GGGTCTAGAGGTACCGTCCG	-----	-----
AT	5' GGGTCTAGAGGTACCGTCCGATCGATCATT	-----	-----
LpA-1A	5' GGAGTCGTGGGGAGCAGTC	coding	671->689
LpA-2	5' GGGAAATTCATGGCGAAGAAGGGC	coding	442->458
LpA-3	5' CCCTGCACTCATGCTCACTTGCCGAGTA	non-coding	810<-827
LpA-5	5' CCCTGCAATTATTGAGATCTTGAG	non-coding	867<-884
LpA-9	5' GTGACAGCCTCGCCGG	non-coding	351<-367
LpA-10	5' CCGTCGACGTACTTCA	non-coding	582<-607

AL and AT are synthetic linker oligonucleotides containing *Xba* I, *Kpn* I and/or *Cla* I restriction sites [22]. The AP sequence is contained within the AT oligomer [22]. LpA-1A, -2, -3, -5, -9 and -10 correspond to the coding or non-coding sequence of *Lol pI*, as indicated. LpA-2 contains an *Eco* RI restriction site, while LpA-3 and -5 contain *Pst* I restriction sites added for cloning purposes. All restriction sites are underlined.

		-20	
2	CAATTAAGGAGCAACCAACAAATTCAGAGACAAG	ATGGCGCTCCTCCTCGTGGTGCCTCCTG	29
		M A S S S V L L	
	-10	1	
	GTGGTGGCGCTGTTCCCGCTGTTCTCTGGGCAGCGCGCATGGCCATCCGGAAGGTACCAACG		119
	V V A L F A V F L G S A H G	<u>T A K V P E</u>	
	10	20	
	GGCCCCAACATCACGGCCGAGTACGGCGACAAAGTGGCTGGACCGCAAGAGCACCTGGTAT		179
	<u>G P N I T A E Y G D K N L D A K S T W Y</u>		
	30	40	
	GGCAAGCCGACCGCGCGCGGTCCCAAGGACAAACGGCGCGCGTGGCGGTACAAAGGACGTC		239
	<u>G K E I G A G P K D N G G A C G Y K D V</u>		
	50	60	
	GACAAGCGCGCTTCAACGGCATGACCGGCTGGCGGCAACCGCCATCTTCAAGGACGGC		299
	<u>D K A P F N G M T G C G N T F I F K D G</u>		
	70	80	
	CGTGGCTCGGCTCCTGCTTCGAGATCAAGTGCACCAAGCCCGAGTCTGCTCCGGCCAG		359
	<u>R G C G S C F E I K C T K P E S C S G E</u>		
	90	100	
	GCTGTACCGCTCACAAATCACCGACGACAAATGAGGAGCCTATCGCACCCCTACCACTTCGAC		419
	<u>A V T V T I T D D N E E P I A P Y H F D</u>		
	110	120	
	CTCTCGGGCC/CGCATTCGGGTCCATGCGGAAGAAGGGCCGAGGAGCAGAAGCTCCGCAGC	13A	479
	<u>L S C H A F G S M A K K G E E Q K L R S</u>		
	130	140	
	GCCGGCGAGCTGGAGCTCCAGTTCAGGCGGGTCAAGTGCAAGTACCCGGACGGCACCAAG		539
	<u>A G E L E L Q F R R V K C K Y P D G T K</u>		
	150	160	
	CCGACATTCCACGTCGAGAAGGCTTCCAACCCCACTACCTCGCTATTCTGGTGAAGTAC		599
	<u>P T F H V E K A S N P N Y L A I L V K Y</u>		
	170	180	
	GTCGACGGCGCAGGTGACGTGGTGGCGGTGGACATCAAGGAGAAGGGCAAGGATAAGTGG		659
	<u>V D G D G D V V A V D I K E K G K D K W</u>		
	190	200	
	ATCGAGCTCAAGGAGTCGTGGGGAGCAGTCTGGAGGATCGACACCCCCGATAAGCTGACG		719
	<u>I E L K E S W G A V W R I D T P D K L T</u>		
	210	220	
	GGCCCATTCACCGTCCGCTACACCACCGAGGGCGGCACCAAAATCCGAAGTCGAGGATGTC		779
	<u>G P F T V R Y T T E G G T K S E V E D V</u>		
	230	240	
	ATCCCTGAGGGCTGGAAGGGCGACACCTCCTACTCGGCCAAGTGAGCAAGAAGTGGAGTG		839
	<u>I P E G W K A D T S Y S A K *</u>		
	ATCTTCTTCCATCAGCTTAATTTTGACTCAAGATCTCAATAATCCAGCCGCACATATA		899
	TACGAGGCGGTGAGACATACAAGCTCCTCCATGAGTATATTCATTTCATGCCGTATAGAGA		959
	GGAGAAAGATGCCTGAATAAGAGTTTGAGGTGCACACCTTGTGAGAAGTGATATAGGAG		1019
	GAACCCCAATCTGGCTCCATCTTTCTTTGCTCGCACGGTGTACTGCTAAGGTTATCTTCTA		1079
	ACAGGCCAGATTAACTACTATCTAATATATGCAACGATGGTCATTTTCCTAAAAAA		1139

### Lolpl hydrophobicity profile



separated *Lol pl* (pI 5.5) in sufficient quantities for N-terminal protein sequence analysis. The sequence obtained was as follows:

IAKVPPGPWI TAEYQDKWLD AK?T-----

This sequence is analogous to that reported by Cottam et al. [12].

### 3.3. Isolation of cDNA clones

The cDNA expression library was screened for clones that expressed epitopes recognised by MAb 40.1. Screening of a total of  $5 \times 10^4$  plaques yielded 18 immuno-positive clones. These clones were plaque-purified, and screened for IgE binding using sera from grass pollen-allergic subjects. Four clones were found to express proteins with affinity for IgE antibodies. Of these, the clone 13R (~ 0.8 kb in size including poly (A)<sup>+</sup> tail), bound strongly to MAbs 40.1, 3.2 and 21.3, all known to preferentially recognise *Lol pl* [10]. Thus, the clone expresses an allergen as defined by recognition of IgE from sera of allergic individuals and was designated as a putative *Lol pl* clone.

### 3.4. Nucleotide sequence of *Lol pl*

cDNA clone 13R, selected by expression screening, contains 764 nucleotides. There are 146 amino acids in the open reading frame (ORF) and the predicted  $M_r$  is 16.2 kDa. The translated amino acid sequence terminates with the 28-amino acid sequence described by Esch and Klapper [13]. Since this clone exhibits strong Mab and IgE binding, the sequence contains both antigenic and allergenic epitopes.

However, mature *Lol pl* has an approximate  $M_r$  of 35 kDa, so the translated reading frame is apparently not full-length. Clone 13R also lacks the NH<sub>2</sub>-terminal sequence defined for *Lol pl* [12], confirming that it is a truncated clone. Full-length *Lol pl* clones were obtained by PCR of rye-grass pollen RNA. Primers based on synthetic linker sequences and *Lol pl*-specific sequences derived from the 3' end of clone 13R were used to generate these clones.

The nucleotide sequence of *Lol pl* is shown in Fig. 2a. There is an open reading frame (ORF) of 789 bp starting with an ATG initiation codon at position 33 and terminating with a TGA stop codon at position 822. This ORF, which has a 64% GC content, corresponds to a polypeptide of 263 amino acids ( $M_r$  29.1 kDa). The proposed translation initiation site and its flanking sequences (nucleotides 29–37) share 67% identity with the



Fig. 3. Tissue-specific expression of *Lol pl* in rye-grass pollen. Northern blot analysis of total RNA from rye-grass pollen, seed, leaf, root and inflorescence using 13R cDNA as a probe.

consensus plant sequence AACAAATGGC [25]. The most critical nucleotide, a purine at position -3, is conserved. Sequence corresponding to the 13R clone starts at nucleotide 474.

The predicted protein sequence has a hydrophobic putative signal peptide sequence of 23 amino acids (Fig. 2 a,b). This is indicative of a mature processed protein of 240 amino acids ( $M_r$  26.6 kDa). The amino acid composition from the deduced sequence, rich in glycine and lysine, is in complete agreement with previous data obtained by amino acid analyses of *Lol pl* protein [26,27]. There is a single potential N-glycosylation site having the characteristic Asn-x-Ser/Thr motif (residues 9–11) in the hydrophilic region of the mature protein (Fig. 2b).

Fig. 2. cDNA, predicted amino acid sequence and hydropathicity profile of *Lol pl* from rye-grass pollen. (a) The nucleotide and deduced amino acid sequence of *Lol pl*. The deduced amino acid sequence represented by the single letter code is shown below the DNA sequence, and begins at the first potential in-frame initiation codon. The open reading frame continues for 263 amino acids and ends with the TGA stop codon denoted by an asterisk. The putative signal peptide is indicated by negative numbers. Underlined amino acids were identified by protein microsequencing (this report; and [12,13]). The arrow indicates the start of the 13R sequence. (b) Hydropathicity profile of predicted amino acid sequence based on the method of Kyte and Doolittle [35] with a window of 7 amino acids.

A search of existing data-bases showed no similarity between the deduced amino acid sequence of *Lol pI* and any other known protein. The *Lol pI* nucleotide sequence was compared with that of the newly identified *Lol pIb* [10] and no sequence homology was observed.

### 3.5. Expression of gene for *Lol pI* in various rye-grass tissues

To determine the tissue specificity of *Lol pI* gene expression, we examined the level of specific transcripts in various tissues. Northern blots probed with cDNA 13R showed hybridization to a single abundant transcript (~ 1350 bases) in pollen (Fig. 3). Hybridization was also observed to similar sized transcripts in inflorescence, but no hybridization to any transcripts in rye-grass seed, leaf or root was observed (Fig. 3).

## 4. DISCUSSION

In this report we describe the cloning of a cDNA sequence encoding an allergen from rye-grass pollen. Several lines of evidence confirm that clone 13R corresponds to the major glycoprotein allergen, *Lol pI*. First, the clone was immunoselected from the lambda-gt 11 expression library using a MAb that shows high levels of binding to *Lol pI*. Second, the polypeptide encoded by the cDNA clone was recognised by IgE antibodies from pooled sera of grass pollen-allergic individuals. Third, a segment of the deduced amino acid sequence of the clone corresponded to the 38-amino acid tryptic fragment of *Lol pI* (YTTEGGTKSEFEDV IPEGW KADTS YSAK) described by Esch and Klappper [13]. Finally, the pollen specificity of transcripts

hybridizing with 13R, is consistent with tissue specificity of *Lol pI* antigens, as observed earlier by immunoblotting [10].

The N-terminal sequence of *Lol pI*, was not detected in the ORF of the 13R clone. However, full length clones obtained by PCR amplification, encoded an amino acid sequence which corresponded with the N-terminal sequence of *Lol pI* ([12]; and this paper). The longest ORF is 789 nucleotides long, which corresponds to a protein of 263 amino acids with a leader sequence of 23 amino acids. The molecular mass for the mature form of *Lol pI* (240 amino acids) was calculated to be 26.6 kDa. This would suggest that 24% of the 35 kDa molecular mass of the pollen protein is due to post-translational modifications.

The *Lol pI* signal peptide has some motifs common to other plant signal peptides, especially those of secreted plant enzymes, e.g. amylase [28]. The motifs close to the cleavage site show some similarity with those of signal peptides which direct proteins into the lumen of the ER for glycosylation, e.g. VLL...FLGSAHC<sup>1</sup> in *Lol pI* and VLL...LSASLASQ<sup>1</sup> in alpha-amylase [28]. The -1 and -3 rule for the prediction of a leader sequence cleavage site [29] is that amino acids at these positions should be small and neutral: G and A in *Lol pI*.

The deduced amino acid sequence of the full length *Lol pI* clone contains both the N-terminal sequence [12] and tryptic peptide fragment sequence [13] previously reported for *Lol pI*, as well as the N-terminal protein sequence of *Lol pI* reported here. The N-terminal sequences ([12]; and this report) helped define the cleavage site between the leader sequence and the mature form of *Lol pI*.

<i>Lol pI</i> IA	E Q K L R S A G E L E L Q F R R V K C K Y P D G	T K P T F H V E R A	154
<i>Lol pI</i> II		A P V E F T V E R G	11
<i>Lol pI</i> III		T K V D L T V E R G	10
<i>Lol pI</i> IA	S N P N Y L A I L V K Y V D G D G D V V A V D I K E K G K D K W		186
<i>Lol pI</i> II	S D E R N L A L S I K Y N K E G D S M A R V E L K R H G S N E W		43
<i>Lol pI</i> III	S D A R T L V L N I R Y T R P G D T L A R V E L R Q H G S E R W		42
<i>Lol pI</i> IA	I E L R E S W G A V H R I D T P D K L T G P F T V R Y T F E G G		218
<i>Lol pI</i> II	L A L K R N G D G V W E I K S D K P L K G P F N R F V S E K G		77
<i>Lol pI</i> III	E P M T R K G N - L W E V K S A R P L T G P M N R F L S K G G		75
<i>Lol pI</i> IA	T R S E V S D V I P E G W K A D T S Y S A K		240
<i>Lol pI</i> II	M R N V F D D V V R A C F R V G T T Y K P E		97
<i>Lol pI</i> III	M R N V F D E V I P T A F T V G K R Y T F E Y N		97

Fig. 4. Homologies of *Lol pI* with *Lol pII* and *Lol pIII*. Alignment of deduced amino acid sequence of *Lol pI* with reported sequences of *Lol pII* [26] and *Lol pIII* [27]. Identical residues are shown in bold letters. These residues and other similar residues in the three sequences are indicated by boxes. The following residues were considered similar: A,S,T; D,E; N,Q; R,K; I,L,M,V; F,Y,W.

Our results show that the 28 amino acid tryptic fragment sequence YTTE GGTGS EFEDV IPEGW KADTS YSAK [13] is located at the COOH-terminus of this allergen. We also found that the entire 97 amino acid sequences of *Lol pII* [30] and *Lol pIII* [31] have strong homology with the COOH-terminal end of *Lol pI* (Fig. 4). *Lol pI* has 48% homology (33% identity) with *Lol pII* and 44% homology (26% identity) with *Lol pIII*, while *Lol pII* and *Lol pIII* have 73% homology (59% identity) with each other. However, despite strong homology between amino acids 145 to 240 of *Lol pI* with the amino acid sequences of *Lol pII* and *Lol pIII*, no serological cross-reactivity has been detected between *Lol pI* and *Lol pII* nor *Lol pIII* [32].

Immune responsiveness to rye-grass pollen allergens in the human population is significantly associated with the histocompatibility leukocyte antigen (HLA)-DR3 [33,34]. One interpretation of this finding is that HLA-DR3, or closely linked class II molecules, may be particularly effective at presenting certain allergenic determinants to T cells. Ansari et al. [30,31] predicted that the 28 amino acid tryptic fragment isolated by Esch and Klapper [13] may include an HLA-DR3 restricted T cell/Ia recognition site. Both *Lol pII* and *Lol pIII* have sequences homologous to this tryptic fragment and Ansari et al. proposed that the *Lol pI* T-cell determinant may be shared with *Lol pII* and *Lol pIII* [30,31]. This may explain the concordant responsiveness of patients to *Lol pI*, *Lol pII* and *Lol pIII* [33,34].

Now that the amino acid sequences of *Lol pI*, II and III are available it should be possible to experimentally determine the T- and B-cell epitopes of these allergens using synthetic peptides based on their sequences.

**Acknowledgements:** We thank the Australian National Health and Medical Research Council, Asthma Foundation of Victoria, Immunologic Pharmaceutical Corporation, and the Australian Government Department of Employment Education and Training for financial support for this project.

## REFERENCES

- [1] Wuthrich, B. (1989) *Int. Arch. Allergy Appl. Immunol.* 90, 3-10.
- [2] McNicholl, K. and Williams, M. (1973) *Br. Med. J.* 4, 16-20.
- [3] Fleming, D.M. and Crombie, D.L. (1987) *Br. Med. J.* 294, 279-283.
- [4] Singh, M.B. and Knox, R.B. (1985) *Int. Archs. Allergy Appl. Immunol.* 78, 300-304.
- [5] Esch, R.E. and Klapper, D.G. (1987) *J. Allergy Clin. Immunol.* 79, 489-495.
- [6] Strandberg, R., Spackman, V. and Porter, G.J. (1987) *Int. Arch. Allergy Appl. Immunol.* 83, 96-103.
- [7] Freidhoff, L.R., Ehrlich-Kautzky, E., Grant, J.H., Meyer, D.A. and Marsh, D.G. (1986) *J. Allergy Clin. Immunol.* 62, 316-325.
- [8] Ford, D. and Baldo, B.A. (1986) *Int. Arch. Allergy Appl. Immunol.* 81, 193-203.
- [9] Marsh, D.G., Goodfriend, L., King, T.P., Lowenstein, H. and Platts-Mills, T.A.E. (1988) *Clin. Allergy* 18, 201-209.
- [10] Singh, M.B., Hough, T., Theerakulpisut, P., Avliloglu, A., Davies, S., Smith, P.M., Taylor, P.E., Simpson, R.J., Ward, L., McCluskey, J., Puy, R. and Knox, R.B. (1990) *Proc. Nat. Acad. Sci. USA*, in press.
- [11] Staff, I.A., Taylor, P.E., Smith, P.M., Singh, M.P. and Knox, R.B. (1990) *Histochem. J.* 22, 276-290.
- [12] Corram, G.P., Moran, D.M. and Strandberg, R. (1986) *Biochem. J.* 234, 305-310.
- [13] Esch, R.E., Klapper, D.G. (1989) *Mol. Immunol.* 26, 557-561.
- [14] Kahn, C.R. and Marsh, D.G. (1986) *Mol. Immunol.* 23, 1281-1288.
- [15] Smart, I.J., Heddl, R.J., Zola, M. and Bradley, J. (1983) *Int. Arch. Allergy Appl. Immunol.* 72, 243-248.
- [16] Knox, R.B., Singh, M.B., Hough, T. and Theerakulpisut, P. (1989) *Adv. Biosci.* 75, 161-171.
- [17] Ward, L.D., Reid, G.E., Moritz, R.L. and Simpson, R.J. (1990) in: *Current Research in Protein Chemistry* (Villafranca, J.J. ed.) pp. 179-193. Academic Press, New York.
- [18] Ward, L.D., Hong, J., Whitehead, R.H. and Simpson, R.J. (1990) *Electrophoresis*, in press.
- [19] Herrin, D. and Michaels, A. (1984) *Plant Mol. Biol. Reporter* 2, 24-29.
- [20] Gubler, U. and Hoffman, B.J. (1983) *Gene* 25, 263-269.
- [21] Sanger, F., Nicklen, S. and Coulson, A.R. (1977) *Proc. Nat. Acad. Sci. USA* 74, 5463-5468.
- [22] Rafnar, T., Griffith, I.J., Kuo, M.-C., Bond, J.F., Rogers, B.L. and Klapper, D.G. (1990) *J. Biol. Chem.*, in press.
- [23] Frohman, M.A., Dush, M.K. and Martin, G.R. (1988) *Proc. Nat. Acad. Sci. USA* 85, 8998-9002.
- [24] Roux, K.H. and Dhanarajan, P. (1990) *BioTech.* 8, 48-57.
- [25] Lutcke, H.A., Chow, K.C., Mickel, F.S., Moss, K.A., Kern, H.F. and Scheele, G.A. (1987) *EMBO J.* 6, 43-48.
- [26] Johnson, P. and Marsh, D.G. (1966) *Immunochemistry* 3, 101-110.
- [27] Howlett, B.J. and Clarke, A.E. (1981) *Biochem. J.* 197, 695-706.
- [28] Jones, R.L. and Robinson, D.G. (1989) *New Phytol.* 111, 567-597.
- [29] Von Heljine, G. (1984) *J. Mol. Biol.* 173, 243-251.
- [30] Ansari, A.A., Shenbagamurthi, P. and Marsh, D.G. (1989) *J. Biol. Chem.* 264, 11181-11185.
- [31] Ansari, A.A., Shenbagamurthi, P. and Marsh, D.G. (1989) *Biochemistry* 28, 8665-8670.
- [32] Ansari, A.A., Kikhar, T.K. and Marsh, D.G. (1987) *J. Immunol.* 139, 4034-4041.
- [33] Freidhoff, L.R., Ehrlich-Kautzky, E., Meyers, D.A., Ansari, A.A., Bias, W.B. and Marsh, D.G. (1988) *Tissue Antigens* 31, 211-219.
- [34] Ansari, A.A., Freidhoff, L.R., Meyers, D.A., Bias, W.B. and Marsh, D.G. (1989) *Hum. Immunol.* 25, 59-71.
- [35] Kyte, J. and Doolittle, R.F. (1982) *J. Mol. Biol.* 157, 105-132.

## NOTE ADDED IN PROOF

Perez et al. (*J. Biol. Chem.* (1990) 265, 16210-16215) have reported the cloning of two *Lol pI* isoforms. We detected the amino acid polymorphisms defined by their two clones in our PCR analysis of rye-grass pollen. In addition, we have identified other potential polymorphic residues (data not shown). This clearly demonstrates that there are multiple *Lol pI* isoforms.